Let’s start with Key Opinion Leaders (KOL).
These folks are highly respected in their field of medical practice.
And biotech firms need them to help with approval for trials, marketing, and insurance to unlock new revenue from doctor prescriptions.
In other words, the right KOL makes a difference for biotech firms, and we found…
A $1 firm with multiple KOLs in a $90 billion marketAclarion (ACON) has software that’s changing how doctors treat back pain.
The market is currently worth about $90 billion.
And ACON has partnerships with several diagnostic companies…
Along with a prominent healthcare giant on the cap table.
Odds are, if its software plays out, it’ll get bought out at a screaming premium.
The stock currently trades at barely $1 per share, but I won’t be surprised if…
A buyout pushes share prices above $20 or more
Handing early investors a 20x return as the company expands its market share.
You’ll probably do well buying ACON before the buyout.
But there are bigger opportunities to harness if you know which biotech firms have…
The most recent and most convincing insider purchasing activities.